- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06063200
Methylphenidate and Response to Alcohol Cues Pilot Study
February 6, 2026 updated by: University of Florida
Methylphenidate and Response to Alcohol Cues (MARA) Pilot Study
The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcohol cues.
The study will observe the effects of methylphenidate or a placebo on attentional bias and craving responses to alcohol cues through fMRI, EEG, and behavioral testing.
Participants will be involved in one remote and two in-person sessions.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Recent studies have revealed a robust link between attentional ability and resilience against stress-related psychopathology, in general, and against alcohol use disorder (AUD) specifically.
For example, self-reported attentional ability correlates with scales of psychological resilience and with lower alcohol misuse in at-risk individuals.
One mechanism by which attention may relate to resilience in AUD is through its effects on alcohol cue reactivity.
Exposure to alcohol cues can induce motivation to drink alcohol for those with AUD.
Leveraging the high rates of co-morbidity of AUD and attention-deficit/hyperactivity disorder, this pilot study seeks to demonstrate whether experimentally enhancing attention in individuals with both AUD and attentional deficits associated with attention-deficit/hyperactivity disorder (ADHD) reduces markers of addiction severity (i.e., craving and attentional bias responses to alcohol cues) and will explore the neural and behavioral mechanisms.
Methylphenidate not only improves sustained attention, but in users of cocaine and methamphetamine, it was previously shown to reduce craving, attentional bias, and neural responses to viewing drug-related cues.
Here we will use this commonly-prescribed medication as a pharmacological probe of attentional processes related to alcohol use disorder.
We hypothesize that acute methylphenidate-associated attentional enhancement will engage compensatory brain mechanisms that will lead to attenuated craving, reduced attentional bias, and modulated neural responses to alcohol cues in young adults with AUD and ADHD.
Thirty young adults with AUD and ADHD will be recruited for a double-blind, placebo-controlled, within-subjects experiment to test the effects of an acute 20 mg MPH administration to increase attention on cue-induced alcohol craving [during simultaneous functional magnetic resonance imaging (fMRI) and EEG] and attentional bias.
Subjects will also perform computerized tasks of general attention with non-alcohol-related stimuli.
The goal of this project is to support the design and funding proposal of a larger study.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adults ages 18-25 years
- Meets DSM-5 criteria for AUD
- Meets DSM-5 criteria for ADHD
- Fluent in English
- Normal or corrected to normal vision
Exclusion Criteria:
- Meets DSM-5 criteria for bipolar disorder, psychotic disorders, neurological disorders, or substance use disorders other than AUD.
- Participant routinely uses psychoactive drugs or medications except for non-dependent marijuana or nicotine use (due to common use of these substances in individuals with AUD).
- Participant has contraindications for taking methylphenidate.
- Participant has contraindications for being in an MRI machine
- Self-reported history of high blood pressure over 140/90 or consistent readings of 140/90 or above upon arrival for a session.
- History of seizure disorder
- Liver disease
- Participant is currently pregnant or trying to become pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: crossover 1: methylphenidate, placebo
methylphenidate (single dose, oral, 20 mg, immediate release) followed by placebo (single dose, oral)
|
Single encapsulated pill
Other Names:
|
|
Other: crossover 2: placebo, methylphenidate
placebo (single dose, oral) followed by methylphenidate (single dose, oral, 20 mg, immediate release)
|
Single encapsulated pill
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neural responses to cues
Time Frame: 15 minutes
|
Cue-elicited EEG and fMRI responses.
We will contrast brain activation following alcohol images with brain activation following neutral images.
|
15 minutes
|
|
Self-reported craving
Time Frame: 15 minutes
|
Craving following presentation of alcohol and neutral images will be reported using 0-10 visual analog scales.
We will contrast craving following the alcohol images with craving following the neutral images.
|
15 minutes
|
|
Accuracy on the attentional blink task
Time Frame: 5 minutes
|
We will contrast accuracy during alcohol distractor trials with neutral distractor trials for "lags" of 8 versus 2 images following the distractor.
|
5 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported anxiety
Time Frame: 15 minutes
|
Anxiety following presentation of alcohol and neutral images will be reported using 0-10 visual analog scales.
We will contrast anxiety following the alcohol images with anxiety following the neutral images.
|
15 minutes
|
|
Continuous performance task omission errors
Time Frame: 5 minutes
|
Total number of omission errors, indexing sustained attention
|
5 minutes
|
|
Attention network task reaction times
Time Frame: 15 minutes
|
response time (RT) difference for no cue vs. central cue ("altering"), RT difference for central cue vs. spatial cue ("orienting"), RT difference for incongruent vs. congruent flankers ("executive control")
|
15 minutes
|
|
Heart rate
Time Frame: 15 minutes
|
Heart rate will be recorded during cue-induced craving.
We will contrast heart rate during the alcohol images and heart rate during the neutral images.
|
15 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2024
Primary Completion (Actual)
July 1, 2025
Study Completion (Actual)
July 1, 2025
Study Registration Dates
First Submitted
September 26, 2023
First Submitted That Met QC Criteria
September 26, 2023
First Posted (Actual)
October 2, 2023
Study Record Updates
Last Update Posted (Actual)
February 10, 2026
Last Update Submitted That Met QC Criteria
February 6, 2026
Last Verified
July 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Substance-Related Disorders
- Chemically-Induced Disorders
- Alcohol-Related Disorders
- Neurodevelopmental Disorders
- Attention Deficit and Disruptive Behavior Disorders
- Alcoholism
- Attention Deficit Disorder with Hyperactivity
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Carboxylic Acids
- Piperidines
- Acids, Carbocyclic
- Phenylacetates
- Methylphenidate
Other Study ID Numbers
- IRB202301428
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
King's College LondonActive, not recruitingAttention-Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder SymptomsUnited Kingdom
-
Cingulate TherapeuticsSuspendedPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcCompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Central South UniversityRecruitingAttention-Deficit/Hyperactivity DisorderChina
-
Qbtech ABEnrolling by invitationAttention Deficit Disorder With Hyperactivity (ADHD) | Attention Deficit Disorder (ADD)United States
-
University of Texas at AustinRecruitingAttention Deficit Hyperactivity DisorderUnited States
-
Rutgers, The State University of New JerseyNational Institute of Mental Health (NIMH); Louisiana State University Health...Recruiting
-
Universidade do Sul de Santa CatarinaAssociação Brasileira de Cannabis MedicinalRecruitingAttention-Deficit/Hyperactivity Disorder (ADHD)Brazil
-
Nanjing Medical UniversityRecruitingAdult Attention Deficit Hyperactivity DisorderChina
Clinical Trials on Methylphenidate Pill
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Not yet recruiting
-
Shalvata Mental Health CenterCompletedAttention Deficit Hyperactivity DisorderIsrael
-
National Institute on Alcohol Abuse and Alcoholism...CompletedNormal PhysiologyUnited States
-
Rambam Health Care CampusCompletedPharmacological Action (PA)Israel
-
ANRS, Emerging Infectious DiseasesHopital Paul BrousseWithdrawn
-
Vrije Universiteit BrusselScience and Research Centre KoperRecruiting
-
University of Alabama at BirminghamCompletedObesity | Body Weight | Eating Behavior | HungerUnited States
-
University of ArkansasCompleted
-
Hugo W. Moser Research Institute at Kennedy Krieger...RecruitingADHD - Attention Deficit Disorder With HyperactivityUnited States
-
NYU Langone HealthCompleted